The "AD Scientific Index" analyses the academic work of scientists using the H-index, i10 index and number of citations, and provides results that can be used to evaluate the productivity and efficiency of individuals and institutions. In addition to ranking according to "total H-index" for individuals and institutions, you can also see the ranking and analyses according to "last 6 years H-index", "total i10 Productivity index", "last 6 years i10 Productivity index", "total citations" and "last 6 years citations" only in "AD Scientific Index". See also: Subject Rankings and University Subject Rankings. Click here for individual or institutional registration.
Only in AD Scientific Index !!!!
Subject Rankings, University Subject Rankings, Citiation Rankings, i10 Productivity Rankings, Country Rankings, Detailed analyses of universities
AD Scientific Index - World Scientists Rankings - 2024 | H INDEX | i10 INDEX | CITATION | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
University / Institution |
Country | Region | World | Name | Country | University / Institution | Subject | Total | Last 6 year | Last 6 year/total | Total | Last 6 year | Last 6 year/total | Total | Last 6 year | Last 6 year/total |
1 | 50 | 2,285 | 6,750 |
|
Denmark | Novo Nordisk A/S |
Others
|
105 | 87 | 0.829 | 292 | 246 | 0.842 | 62,995 | 33,435 | 0.531 |
2 | 228 | 8,442 | 24,697 |
|
Denmark | Novo Nordisk A/S |
Others
Atherosclerosis | Heart Failure | Diabetes | NASH | Obesity | |
74 | 29 | 0.392 | 165 | 68 | 0.412 | 22,992 | 3,222 | 0.140 |
7 | 1,188 | 44,920 | 124,503 |
|
Denmark | Novo Nordisk A/S |
Others
Isotope Labelling | Drug design | Synthesis | |
41 | 25 | 0.610 | 61 | 44 | 0.721 | 4,335 | 1,733 | 0.400 |
8 | 1,560 | 60,262 | 165,918 |
|
Denmark | Novo Nordisk A/S |
Others
Obesity | appetite regulation | |
36 | 21 | 0.583 | 65 | 46 | 0.708 | 4,856 | 2,101 | 0.433 |
10 | 1,765 | 68,232 | 187,254 |
|
Denmark | Novo Nordisk A/S |
Others
|
34 | 18 | 0.529 | 63 | 29 | 0.460 | 4,261 | 1,190 | 0.279 |
11 | 1,873 | 72,161 | 198,154 |
|
Denmark | Novo Nordisk A/S |
Others
Health authority interactions | GLP-1 RAs | biomarkers | inflammation | type 2 diabetes | |
33 | 19 | 0.576 | 35 | 25 | 0.714 | 6,050 | 1,518 | 0.251 |
12 | 1,950 | 75,425 | 207,442 |
|
Denmark | Novo Nordisk A/S |
Others
|
32 | 22 | 0.688 | 59 | 35 | 0.593 | 3,071 | 1,358 | 0.442 |
13 | 2,011 | 78,111 | 214,531 |
|
Denmark | Novo Nordisk A/S |
Others
Stem Cell Engineering | Cell Therapy | Glycoengineering | |
31 | 28 | 0.903 | 38 | 38 | 1.000 | 3,648 | 3,112 | 0.853 |
15 | 2,312 | 90,857 | 249,483 |
|
Denmark | Novo Nordisk A/S |
Others
|
29 | 20 | 0.690 | 54 | 35 | 0.648 | 2,909 | 1,078 | 0.371 |
16 | 2,345 | 92,483 | 253,424 |
|
Denmark | Novo Nordisk A/S |
Others
|
29 | 16 | 0.552 | 51 | 23 | 0.451 | 4,979 | 1,043 | 0.209 |
Click for INSTITUTIONAL REGISTRATION and PREMIUM MEMBERSHIP advantages |
||||||||||||||||
22 | 2,772 | 112,054 | 306,632 |
|
Denmark | Novo Nordisk A/S |
Others
|
26 | 14 | 0.538 | 39 | 19 | 0.487 | 2,026 | 656 | 0.324 |
23 | 2,893 | 118,108 | 323,958 |
|
Denmark | Novo Nordisk A/S |
Others
|
25 | 16 | 0.640 | 43 | 24 | 0.558 | 2,110 | 650 | 0.308 |
24 | 2,929 | 120,170 | 328,942 |
|
Denmark | Novo Nordisk A/S |
Others
|
25 | 9 | 0.360 | 36 | 8 | 0.222 | 3,281 | 548 | 0.167 |
28 | 3,341 | 139,479 | 384,372 |
|
Denmark | Novo Nordisk A/S |
Others
single cell RNA sequencing | system biology | molecular disease understanding. | |
22 | 19 | 0.864 | 28 | 27 | 0.964 | 3,436 | 1,774 | 0.516 |
29 | 3,363 | 140,426 | 387,149 |
|
Denmark | Novo Nordisk A/S |
Others
|
22 | 18 | 0.818 | 29 | 28 | 0.966 | 4,536 | 2,492 | 0.549 |
30 | 3,405 | 142,442 | 392,526 |
|
Denmark | Novo Nordisk A/S |
Others
|
22 | 16 | 0.727 | 29 | 23 | 0.793 | 2,633 | 1,856 | 0.705 |
31 | 3,565 | 150,149 | 414,853 |
|
Denmark | Novo Nordisk A/S |
Others
Drug Discovery | Cardiometabolic Diseases | |
21 | 17 | 0.810 | 30 | 25 | 0.833 | 1,498 | 1,015 | 0.678 |
32 | 3,604 | 151,519 | 418,663 |
|
Denmark | Novo Nordisk A/S |
Others
|
21 | 16 | 0.762 | 26 | 24 | 0.923 | 1,540 | 945 | 0.614 |
34 | 3,621 | 152,612 | 421,611 |
|
Denmark | Novo Nordisk A/S | Others | 21 | 15 | 0.714 | 24 | 19 | 0.792 | 1,962 | 501 | 0.255 |
35 | 3,634 | 153,531 | 423,928 |
|
Denmark | Novo Nordisk A/S |
Others
|
21 | 14 | 0.667 | 24 | 17 | 0.708 | 4,497 | 1,535 | 0.341 |
36 | 3,736 | 158,761 | 439,219 |
|
Denmark | Novo Nordisk A/S |
Others
|
20 | 18 | 0.900 | 21 | 18 | 0.857 | 3,880 | 2,524 | 0.651 |
37 | 3,824 | 163,643 | 452,944 |
|
Denmark | Novo Nordisk A/S |
Others
Platelet biology | hemostasis | coagulation | vascular medicine | |
20 | 14 | 0.700 | 22 | 18 | 0.818 | 2,160 | 739 | 0.342 |
38 | 3,847 | 166,271 | 459,395 |
|
Denmark | Novo Nordisk A/S |
Others
|
20 | 10 | 0.500 | 24 | 10 | 0.417 | 2,157 | 419 | 0.194 |
40 | 3,899 | 169,483 | 469,721 |
|
Denmark | Novo Nordisk A/S |
Others
Chromatography | Cyclic adsorption processes | downstream processes | CO2 capture | |
19 | 17 | 0.895 | 26 | 21 | 0.808 | 1,361 | 955 | 0.702 |
42 | 3,948 | 171,454 | 475,572 |
|
Denmark | Novo Nordisk A/S |
Others
Cardiometabolic Disease | Drug Discovery | |
19 | 16 | 0.842 | 21 | 19 | 0.905 | 1,193 | 622 | 0.521 |
45 | 4,169 | 181,938 | 505,639 |
|
Denmark | Novo Nordisk A/S |
Others
Insulin signalling | Adipose tissue biology | Diabetes | |
18 | 16 | 0.889 | 21 | 17 | 0.810 | 2,553 | 777 | 0.304 |
48 | 4,251 | 186,484 | 518,461 |
|
Denmark | Novo Nordisk A/S |
Others
diabetes | |
18 | 13 | 0.722 | 24 | 15 | 0.625 | 2,652 | 568 | 0.214 |
51 | 4,300 | 190,384 | 528,175 |
|
Denmark | Novo Nordisk A/S |
Others
NMR | |
18 | 9 | 0.500 | 22 | 9 | 0.409 | 1,251 | 588 | 0.470 |
55 | 4,622 | 207,575 | 579,539 |
|
Denmark | Novo Nordisk A/S |
Others
|
16 | 15 | 0.938 | 16 | 16 | 1.000 | 1,314 | 1,025 | 0.780 |
57 | 4,844 | 220,307 | 616,105 |
|
Denmark | Novo Nordisk A/S |
Others
Quantum Communications | Orbital angular momentum | |
15 | 15 | 1.000 | 15 | 15 | 1.000 | 1,119 | 1,100 | 0.983 |
A New and Different Feature!!!! University Subject Rankings in 12 subjects:Ranking and analysis of universities by subject in 12 fields such as health, engineering, natural sciences, education, business, economics, social sciences, etc. |
||||||||||||||||
62 | 5,000 | 229,047 | 642,737 |
|
Denmark | Novo Nordisk A/S |
Others
Metabolism | drug discovery | thermogenesis | energy balance | neuroscience | |
15 | 11 | 0.733 | 16 | 11 | 0.688 | 2,039 | 866 | 0.425 |
70 | 5,390 | 253,930 | 715,968 |
|
Denmark | Novo Nordisk A/S |
Others
Drug delivery | peptide/protein formulation | |
13 | 12 | 0.923 | 15 | 15 | 1.000 | 1,213 | 974 | 0.803 |
71 | 5,434 | 256,395 | 723,681 |
|
Denmark | Novo Nordisk A/S |
Others
|
13 | 11 | 0.846 | 16 | 14 | 0.875 | 1,686 | 1,167 | 0.692 |
72 | 5,451 | 257,448 | 726,962 |
|
Denmark | Novo Nordisk A/S |
Others
|
13 | 11 | 0.846 | 14 | 12 | 0.857 | 1,246 | 405 | 0.325 |
73 | 5,459 | 257,893 | 728,484 |
|
Denmark | Novo Nordisk A/S |
Others
|
13 | 11 | 0.846 | 13 | 13 | 1.000 | 1,829 | 486 | 0.266 |
74 | 5,461 | 257,982 | 728,831 |
|
Denmark | Novo Nordisk A/S |
Others
Ion channels | Neuroscience | |
13 | 11 | 0.846 | 13 | 12 | 0.923 | 970 | 408 | 0.421 |
75 | 5,539 | 264,255 | 745,540 |
|
Denmark | Novo Nordisk A/S |
Others
Research | |
13 | 8 | 0.615 | 15 | 6 | 0.400 | 1,076 | 569 | 0.529 |
81 | 5,736 | 274,731 | 777,488 |
|
Denmark | Novo Nordisk A/S |
Others
drug design | therapeutics | |
12 | 10 | 0.833 | 14 | 11 | 0.786 | 768 | 566 | 0.737 |
86 | 5,861 | 286,226 | 809,306 |
|
Denmark | Novo Nordisk A/S |
Others
|
11 | 11 | 1.000 | 12 | 12 | 1.000 | 1,474 | 1,147 | 0.778 |
87 | 5,918 | 289,899 | 821,841 |
|
Denmark | Novo Nordisk A/S |
Others
|
11 | 10 | 0.909 | 12 | 10 | 0.833 | 1,304 | 921 | 0.706 |
Only in AD Scientific Index !!!!Subject Rankings, University Subject Rankings, Citiation Rankings, i10 Productivity Rankings, Country Rankings, Detailed analyses of universities |
||||||||||||||||
88 | 5,941 | 291,376 | 826,852 |
|
Denmark | Novo Nordisk A/S |
Others
(Process) Systems Engineering | Multiscale modelling | |
11 | 10 | 0.909 | 11 | 10 | 0.909 | 816 | 501 | 0.614 |
91 | 6,021 | 297,908 | 845,495 |
|
Denmark | Novo Nordisk A/S |
Others
|
11 | 8 | 0.727 | 11 | 7 | 0.636 | 668 | 366 | 0.548 |
92 | 6,064 | 303,142 | 858,026 |
|
Denmark | Novo Nordisk A/S |
Others
|
11 | 4 | 0.364 | 12 | 0 | 0.000 | 383 | 38 | 0.099 |
93 | 6,103 | 305,370 | 866,084 |
|
Denmark | Novo Nordisk A/S |
Others
|
10 | 10 | 1.000 | 10 | 10 | 1.000 | 1,258 | 751 | 0.597 |
104 | 6,260 | 316,511 | 901,400 |
|
Denmark | Novo Nordisk A/S |
Others
Protein Biophysics | |
10 | 7 | 0.700 | 10 | 6 | 0.600 | 651 | 224 | 0.344 |
105 | 6,294 | 320,463 | 911,233 |
|
Denmark | Novo Nordisk A/S |
Others
Semantic Integration | |
10 | 5 | 0.500 | 10 | 3 | 0.300 | 581 | 219 | 0.377 |
108 | 6,406 | 327,353 | 935,330 |
|
Denmark | Novo Nordisk A/S |
Others
|
9 | 8 | 0.889 | 9 | 8 | 0.889 | 565 | 303 | 0.536 |
110 | 6,454 | 331,143 | 948,186 |
|
Denmark | Novo Nordisk A/S |
Others
|
9 | 7 | 0.778 | 9 | 7 | 0.778 | 630 | 146 | 0.232 |
112 | 6,523 | 340,190 | 972,468 |
|
Denmark | Novo Nordisk A/S |
Others
Toxicologic Pathology | |
8 | 8 | 1.000 | 8 | 7 | 0.875 | 803 | 472 | 0.588 |
116 | 6,593 | 345,725 | 993,985 |
|
Denmark | Novo Nordisk A/S |
Others
|
8 | 7 | 0.875 | 8 | 7 | 0.875 | 583 | 471 | 0.808 |